myasthenia gravis

Text-only Preview

Johnny Nguyen
Thursday – Section 4
April 7, 2011

 What is Myasthenia Gravis?
 Who can be diagnosed with Myasthenia
Gravis?
 How can it be treated?
 Clinical study of a treatment drug

 Definition
 A chronic autoimmune neuromuscular disease that
causes different degrees of voluntary muscle weakness
throughout the body.
 Pathophysiology
 Antibodies produced by our own immune system
destroy, block, or alter acetylcholine receptors at the
neuromuscular junction which put a stop to a contraction
of a muscle.
 Prevalence
 Population most commonly affected are young adult
women and older men, but can occur in anyone
regardless of age and race.
 Symptoms

Image Credit: http://www.myasthenia-gbspk.org/res.aspx

 Pharmacological Treatment
 Prograf (Tacrolimus) – Top 200 drug
 Therapeutic Class – Immunosuppressant
 Adverse Effects : Headache, Constipation, Nausea
 Prostigmin(Neostigmine Bromide)
 Therapeutic Class – Anticholinesterase
 Adverse Effects: Excessive salivation, Muscle
fasciculation
 Non-pharmacological Treatment
 Plasmapheresis
 Thymectomy

120
100
) 80
a
l (%
60
Thymectomised
S
u
r
v
iv

40
Non-Thymectomised
20
0
0
3
5
10
20
Years from Diagnosis
Reference: Christensen, P. B., Jensen, T. S., Tsiropoulos, I. I., Sorensen, T. T., Kjaer, M. M., Hojer-Pedersen, E. E., &
... Lehfeldt, E. E. (1998). Mortality and survival in myasthenia gravis: A Danish population based study.Journal of
Neurology Neurosurgery and Psychiatry, 64(1), 78-83.

Study
A clinical study for the use of
tacrolimus to treat myasthenia
gravis
Methods
212 patients with myasthenia
gravis
nonrandomized and
noncontrolled
study
Finding/Results
Improvement of muscular
strength in a large amount of
patients with MG
Conclusions
Tacrolimus in low-doses proved to
be effective for treatment
Personal Perspective
Muscular strength improvement is
a great factor for patient
compliance for this drug.


Christensen, P. B., Jensen, T. S., Tsiropoulos, I. I., Sorensen, T. T.,
Kjaer, M. M., Hojer-Pedersen, E. E., & ... Lehfeldt, E. E. (1998).
Mortality and survival in myasthenia gravis: A Danish population
based study.Journal of Neurology Neurosurgery and Psychiatry, 64(1),
78-83.

Micromedex – Search Drug name for Adverse Effects

Myasthenia Gravis Fact Sheet: National Institute of Neurological
Disorders and Stroke (NINDS). (n.d.).National Institute of
Neurological Disorders and Stroke (NINDS). Retrieved March 28,
2011, from
http://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_
myasthenia_gravis.htm

Ponseti, J., Gamez, J., Azem, J., López-Cano, M., Vilallonga, R., &
Armengol, M. (2008). Tacrolimus for myasthenia gravis: a clinical
study of 212 patients. Annals Of The New York Academy Of Sciences,
1132254-263. Retrieved from EBSCOhost.

PMWO : Pakistan Myasthenia Gravis Welfare Organization .
(n.d.). PMWO :: Pakistan Myasthenia Gravis Welfare Organization .
Retrieved March 28, 2011, from http://www.myasthenia-
gbspk.org/res.aspx

Document Outline

  • ÿ
  • ÿ
  • ÿ
  • ÿ